International Flavors & Fragrances Inc.

▲ Bull Case

• ◆Food Ingredients divestiture announced by mid-FY2026 at 9–11x EBITDA, generating $2.5–3.0B in proceeds; net debt falls to ~$3B (Net Debt/EBITDA ~1.3–1.8x); EBITDA margin improves to 22–23% on retained portfolio; adj. EPS reaches $5.75; multiple re-rates to 20x adj. P/E → price target $110 (+53% total return). Icahn's activist mandate and clear strategic rationale (Food Ingredients was never core IFF) drive execution.
• ◆CapEx normalization from $594M (FY2025) to $375–425M (FY2026) is the most certain near-term catalyst, mechanically generating an additional $170–220M in FCF — a 68% FCF improvement — without any revenue or margin improvement. This is already management-guided and in-progress, with cash impact visible in Q2–Q3 2026 quarterly FCF reports.
• ◆EBITDA margin recovery from 18–19% toward 20–22% driven by the $400M cost savings program ($250M already realized through FY2025), CPG customer destocking cycle completion driving volume/mix improvement, and portfolio rationalization. At 20% margin on $11B revenue, EBITDA reaches ~$2.2B vs. ~$2.0B today — worth ~$500M in EV at 12x and ~$2/share in incremental FCF. Institutional anchor base (Dodge & Cox + Icahn board discipline) reduces capital misallocation risk.

▼ Bear Case

• ◆EBITDA margin recovery stalls at 18–19% as cost savings program underdelivers and CPG destocking benefits do not materialize; Food Ingredients sale is abandoned; CapEx normalizes only to $490M in FY2026 rather than the guided $375–425M. Organic revenue growth remains 0–1%, Net Debt/EBITDA stays elevated at ~2.6x, and the multiple de-rates to 12.5x adj. P/E → price ~$53 (−24.1% total return).
• ◆Leverage remains a persistent risk: Net Debt/EBITDA at ~2.9x (FY2025) limits financial flexibility and keeps the cost of capital elevated. Any new goodwill impairment or EBITDA decline could push leverage above 3.5x, triggering potential credit agency downgrade to BB and materially increasing refinancing risk — particularly as the DuPont N&B integration costs continue to weigh on free cash flow.
• ◆The N&B merger overhang persists structurally: $10B+ in goodwill impairments have destroyed GAAP earnings credibility, ROIC at 5.8% is 220bps below WACC, and IFF trades at a 30–40% EV/EBITDA discount to Symrise (16–18x) and an even wider discount to Givaudan. If portfolio rationalization stalls and the market loses patience with the restructuring timeline, the discount could widen further rather than compress.

“Wall Street consensus price target of ~$91.58 essentially prices the base case — approximately 18x FY2027E adj. P/E — with no premium assigned for the Food Ingredients divestiture catalyst. The core debate is: (1) Will IFF successfully divest Food Ingredients at a value-accretive multiple (9–11x EBITDA), and does Icahn's board presence provide sufficient pressure to force execution? (2) Is the EBITDA margin recovery trajectory toward 20–22% credible given IFF's persistent underperformance vs. Symrise and Givaudan peers? (3) Does CapEx normalization ($375–425M guided for FY2026) represent a genuine structural step-down or a temporary reduction? Bulls argue that the Food Ingredients sale is underpriced by the market and that the convergence of Icahn activism + Dodge & Cox long-term anchoring creates a governance structure that forces value-accretive decisions. Bears argue that IFF has a history of disappointing on margin recovery, the N&B integration was strategically flawed, and the Food Ingredients business may fail to attract bids at management's expected valuations — leaving the company with an overleveraged, margin-impaired portfolio and no near-term re-rating catalyst.”

• ◆Food Ingredients divestiture announcement at 9–11x EBITDA ($2.5–3.0B proceeds); would reduce Net Debt/EBITDA from ~2.9x to ~1.3–1.8x and trigger premium re-rating toward $110–120
• ◆Q2 FY2026 earnings CapEx confirmation below $425M — validates FCF recovery from $256M to $400–450M (+68%) and removes most certain near-term execution risk
• ◆EBITDA margin guidance for FY2026 at or above 20% — confirms $400M cost savings program delivery and destocking cycle reversal; would support base case re-rating toward $90
• ◆Icahn-driven strategic review announcement or investor day restructuring update — any formal disclosure of Food Ingredients sale process timeline or buyer shortlist
• ◆Credit rating upgrade or Net Debt/EBITDA declining below 2.0x — signals leverage normalization and enables re-rating from 'restructuring discount' to 'quality specialty chemicals' peer multiple

• ◆Food Ingredients divestiture fails to attract adequate bids or is formally abandoned — removes primary re-rating catalyst; stock likely re-rates toward lower end of bear case ($53)
• ◆EBITDA margin recovery stalls below 19.5% — cost savings program underdelivers; CPG destocking benefits do not materialize; bear case probability rises materially
• ◆CapEx normalization delayed (FY2026 guide maintained above $500M) — most certain near-term FCF catalyst removed; 12–18 month delay to recovery narrative
• ◆Net Debt/EBITDA rises above 3.5x or credit agency downgrade to BB — refinancing risk materializes; leverage trajectory reverses; institutional holders may apply exit pressure
• ◆Icahn exits board seats AND Dodge & Cox reduces position by more than 25% simultaneously — activist governance mandate removed and largest long-term anchor loses confidence; institutional support structure collapses